PPI-1019 (APAN)

DRUG2 trials

Sponsors

PRAECIS Pharmaceuticals Inc.

Conditions

Alzheimer's Disease

Phase 1

Safety Study of PPI-1019 in Patients With Mild-Moderate Alzheimer's Disease

CompletedNCT00100282

PRAECIS Pharmaceuticals Inc.Alzheimer's Disease

Start: 2003-05-31End: 2005-06-30Target: 125Updated: 2006-09-19

Safety Study of PPI-1019 in Subjects With Mild-Moderate Alzheimer's Disease

CompletedNCT00100334

PRAECIS Pharmaceuticals Inc.Alzheimer's Disease

Start: 2004-12-31End: 2005-08-31Target: 24Updated: 2006-09-19